DURECT Reports Completion Of 90 mg Severe Cohort, Dose Escalation Committee Approval To Commence 150 mg Dosing In Patients With Severe Alcoholic Hepatitis In Ongoing DUR-928 Phase 2a AH Trial
Benzinga Newsdesk